Most Favored Nation Pricing is Back – With a Vengeance
FDA Law Blog: Biosimilars
MAY 12, 2025
MFN pricing reemerged in todays Executive Order, which goes well beyond the 2020 order. It sets forth three directives: HHS shall consider facilitating direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation (MFN) price.
64 
Let's personalize your content